These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 21852019

  • 1. Is complement a culprit in infection-induced forms of haemolytic uraemic syndrome?
    Johnson S, Waters A.
    Immunobiology; 2012 Feb; 217(2):235-43. PubMed ID: 21852019
    [Abstract] [Full Text] [Related]

  • 2. Eculizumab in the treatment of Shiga toxin haemolytic uraemic syndrome.
    Walsh PR, Johnson S.
    Pediatr Nephrol; 2019 Sep; 34(9):1485-1492. PubMed ID: 30058046
    [Abstract] [Full Text] [Related]

  • 3. Complement activation in thrombotic microangiopathy.
    Karpman D, Tati R.
    Hamostaseologie; 2013 May 29; 33(2):96-104. PubMed ID: 23411690
    [Abstract] [Full Text] [Related]

  • 4. STEC-HUS, atypical HUS and TTP are all diseases of complement activation.
    Noris M, Mescia F, Remuzzi G.
    Nat Rev Nephrol; 2012 Nov 29; 8(11):622-33. PubMed ID: 22986360
    [Abstract] [Full Text] [Related]

  • 5. Pathophysiology of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome.
    Kremer Hovinga JA, Heeb SR, Skowronska M, Schaller M.
    J Thromb Haemost; 2018 Apr 29; 16(4):618-629. PubMed ID: 29356300
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Hemolytic uremic syndrome.
    Mele C, Remuzzi G, Noris M.
    Semin Immunopathol; 2014 Jul 29; 36(4):399-420. PubMed ID: 24526222
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Atypical haemolytic uraemic syndrome.
    Kavanagh D, Goodship TH, Richards A.
    Br Med Bull; 2006 Jul 29; 77-78():5-22. PubMed ID: 16968692
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Activation of the alternative pathway of complement during the acute phase of typical haemolytic uraemic syndrome.
    Ferraris JR, Ferraris V, Acquier AB, Sorroche PB, Saez MS, Ginaca A, Mendez CF.
    Clin Exp Immunol; 2015 Jul 29; 181(1):118-25. PubMed ID: 25677399
    [Abstract] [Full Text] [Related]

  • 14. Shiga toxin associated hemolytic uremic syndrome.
    Keir LS.
    Hematol Oncol Clin North Am; 2015 Jun 29; 29(3):525-39. PubMed ID: 26043390
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Haemolytic uraemic syndrome: an overview.
    Amirlak I, Amirlak B.
    Nephrology (Carlton); 2006 Jun 29; 11(3):213-8. PubMed ID: 16756634
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.